Table 3.
In-hospital management and outcomes by group among unadjusted and propensity-matched cohorts, stratified by statin therapy.
| Variables | Overall population (N = 842) | Unadjusted data |
Propensity score matched data |
||||
|---|---|---|---|---|---|---|---|
| Statin group (N = 179) | No-statin group (N = 663) | P-value | Statin group (N = 145) | No-statin group (N = 145) | P-value | ||
| In-hospital treatment, N (%) | |||||||
| Non-invasive ventilation | 286 (34) | 66 (37) | 220 (33) | 0.355 | 49 (34) | 50 (34) | 0.902 |
| Oxygen suypport | 651 (77) | 154 (86) | 497 (75) | 0.002 | 122 (84) | 114 (79) | 0.229 |
| Intubation | 42 (5) | 6 (3) | 36 (5) | 0.258 | 6 (4) | 10 (7) | 0.305 |
| Antibiotics | 371 (44) | 84 (47) | 287 (43) | 0.385 | 65 (45) | 85 (59) | 0.019 |
| Corticosteroids | 93 (11) | 23 (13) | 70 (11) | 0.386 | 17 (12) | 18 (12) | 0.858 |
| Hydroxychloroquine | 680 (81) | 152 (85) | 528 (80) | 0.112 | 121 (83) | 120 (83) | 0.876 |
| Antiviral therapy | 466 (55) | 93 (52) | 373 (56) | 0.304 | 72 (50) | 96 (66) | 0.040 |
| Heparin | 382 (47) | 94 (53) | 298 (45) | 0.072 | 70 (48) | 63 (43) | 0.411 |
| Tocilizumab | 126 (15) | 24 (13) | 102 (15) | 0.511 | 19 (13) | 12 (8) | 0.185 |
| Outcomes, N (%) | |||||||
| ICU admission | 46 (5) | 6 (3) | 40 (6) | 0.162 | 6 (4) | 11 (8) | 0.213 |
| ARDS | 155 (18) | 41 (23) | 114 (17) | 0.080 | 24 (17) | 32 (22) | 0.235 |
| Myocardial Injury | 96 (11) | 35 (20) | 61 (9) | < .001 | 25 (17) | 28 (19) | 0.670 |
| Acute kidney injury | 26 (3) | 5 (3) | 21 (3) | 0.798 | 4 (3) | 9 (6) | 0.157 |
| Septic Shock/Sepsis | 19 (2) | 5 (3) | 14 (2) | 0.586 | 4 (3) | 4 (3) | 1.000 |
| Death | 182 (22) | 52 (29) | 130 (20) | 0.006 | 38 (26) | 41 (28) | 0.185 |
| Hospital stay, days | 9 (5–15) | 11 (6–16) | 9 (5–14) | 0.026 | 11 (6–16) | 11 (7–16) | 0.920 |
ICU = intensive care unit; ARDS = acute respiratory distress syndrome.